DHM
Dihydromyricetin (Ampelopsin)
A flavonoid from the Japanese raisin tree that supports liver health and alcohol metabolism recovery.
Dihydromyricetin (DHM) is a flavonoid extracted from Hovenia dulcis (Japanese raisin tree), traditionally used in Asian medicine for hangovers and liver health. Research shows DHM enhances alcohol metabolism enzymes and has hepatoprotective effects. It's gaining popularity as a natural support for those who drink alcohol and for general liver health.
Mechanisms of Action
Enzyme Enhancement
Boosts alcohol-metabolizing enzymes
Liver Protection
Protects liver cells from damage
GABA Modulation
May counteract alcohol's effects on GABA receptors
Recommended Dose
300-600mg before or after drinking; 300mg daily for liver support
Loading: For alcohol occasions: 300mg before drinking, 300mg before bed
Optimal Timing
- Before drinking alcohol
- Before bed after drinking
- Daily for liver support
Take with food
Best Form
Dihydromyricetin capsules or tablets
Alternatives: Hovenia dulcis extract
Look for standardized DHM content. Often found in 'hangover' supplement blends.
Duration
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Not required
Note: For alcohol-related use, take before drinking and again before sleep. Can also be used as ongoing liver support.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Faster Alcohol Metabolism
Quicker clearance of alcohol and acetaldehyde
Liver Protection
Reduced liver stress from alcohol
Hangover Reduction
May reduce next-day symptoms
Consult doctor; may be helpful but need monitoring
Who Should NOT Take This
- Known allergy or hypersensitivity to DHM or related compounds
Drug Interactions
May affect drug metabolism
Possible Side Effects
Tip: Take with food
Warnings
- Does not make drinking safe or prevent intoxication
- Don't use to enable drinking more
Top studies from 40+ peer-reviewed papers
Zhou R et al. • International journal of molecular sciences (2025)
“A deeper understanding of autophagy's regulatory networks, particularly involving these critical genes and proteins, may lead to novel therapeutic approaches for treating metabolic cardiomyopathy.”
Key Findings:
- Additionally, selective autophagy processes such as lipophagy, regulated by PNPLA8, and ferritinophagy, modulated by NCOA4, play pivotal roles in lipid metabolism and iron homeostasis.
- Emerging therapeutic strategies targeting autophagy, including plant extracts (e.g., curcumin, dihydromyricetin), endogenous compounds (e.g., sirtuin 3, LC3), and lipid/glucose-lowering drugs, offer promising avenues for mitigating the effects of metabolic cardiomyopathy.
- Despite recent advances, the precise mechanisms underlying autophagy in this context remain poorly understood.
- A deeper understanding of autophagy's regulatory networks, particularly involving these critical genes and proteins, may lead to novel therapeutic approaches for treating metabolic cardiomyopathy.
Keshavarzian E et al. • Reviews on recent clinical trials (2023)
“This meta-analysis showed that prophylactic treatment with cardio-protective drugs, including dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with anthracycline, have a protective effect on LVEF and prevent EF drop.”
Key Findings:
- Through comparison of the two groups, EF was found to increase in the intervention group by 0.40 after 6 months (Standardized mean difference (SMD): 0.40, 95% confidence interval (CI): 0.27, 0.54), thus proving higher than that of the control groups following the cardiac drugs.
- This meta-analysis showed that prophylactic treatment with cardio-protective drugs, including dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with anthracycline, have a protective effect on LVEF and prevent EF drop.
- Further research warranted to confirm findings
Li S et al. • Cell proliferation (2023)
“This review systematically illustrates that various polyphenols, including resveratrol, chlorogenic acid, caffeic acid, dihydromyricetin, quercetin, catechins, curcumin, etc., improve metabolic disorders through direct or indirect pathways to protect the liver and fight liver cancer.”
Key Findings:
- This review systematically illustrates that various polyphenols, including resveratrol, chlorogenic acid, caffeic acid, dihydromyricetin, quercetin, catechins, curcumin, etc., improve metabolic disorders through direct or indirect pathways to protect the liver and fight liver cancer.
- Published in Cell proliferation (2023)
- Further research warranted to confirm findings
Sayed AM et al. • Life sciences (2020)
“All rights reserved.”
Key Findings:
- Additionally, molecular modeling simulations were applied to explore the potential binding mode of these flavonoids to SIRT1.
- The complied information and molecular docking simulations suggested that SIRT1 signaling is involved in the beneficial pharmacologic activities of flavonoids in different hepatic diseases.Copyright © 2020 Elsevier Inc.
- All rights reserved.
Lin R et al. • Pharmacological research (2025)
“All rights reserved.”
Key Findings:
- This review aims to provide a theoretical framework and translational guidance for developing HF-targeted therapeutic strategies based on Sirtuin-mediated macrophage polarization, as well as for the research and development of related natural products.Copyright © 2025 The Authors.
- Published by Elsevier Ltd..
- All rights reserved.
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.